Ruxolitinib Plus Decitabine Effectively Treats Myelodysplastic Syndrome/Myeloproliferative Neoplasm, Unclassifiable, by Decreasing the Variant Allele Frequency of KRAS

Ruxolitinib Plus Decitabine Effectively Treats Myelodysplastic Syndrome/Myeloproliferative Neoplasm, Unclassifiable, by Decreasing the Variant Allele Frequency of KRAS

Shuna Luo,1 Xiaofei Xu,1 Xingnong Ye,1,2 Xiaoqiong Zhu,1 Cai Wu,1 Dan Chen,1 Jingxia Jin,1 Yan Zheng,1 Mengli Zheng,1 Jian Huang1,2 1Department of Hematology, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu, Zhejiang, People’s Republic of China; 2Department o...

Full description

Bibliographic Details
Main Authors: Luo S, Xu X, Ye X, Zhu X, Wu C, Chen D, Jin J, Zheng Y, Zheng M, Huang J
Format: Article
Language:English
Published: Dove Medical Press 2020-10-01
Series:OncoTargets and Therapy
Subjects:
myelodysplastic syndrome
myeloproliferative neoplasm
decitabine
ruxolitinib
kras
Online Access:https://www.dovepress.com/ruxolitinib-plus-decitabine-effectively-treats-myelodysplastic-syndrom-peer-reviewed-article-OTT

Internet

https://www.dovepress.com/ruxolitinib-plus-decitabine-effectively-treats-myelodysplastic-syndrom-peer-reviewed-article-OTT

Similar Items